Alkem Laboratories Limited Share Price & Analysis
₹5,250Updated 5 Jun 2026, 03:30 pm IST
LTP
₹5,250
—
Open
₹5,299.5
High
₹5,338.5
Low
₹5,222.5
Close
₹5,276.5
52W High
₹5,934
52W Low
₹4,716
Volume
144K
Lot Size
125
Sector
Healthcare
Market Cap
₹63K Cr
Face Value
₹2
Large CapNIFTY 200NIFTY 500MIDCAP 100
Price Chart
Fundamentals
P/E
25.7
Sector P/E
48.9
P/B
4.54
EPS
₹198.32
ROE
18.9%
ROCE
21.2%
D/E Ratio
0.15
Div Yield
0.86%
Book Value
₹1,156
+
Strengths
- ✓Strong return on equity (ROE 18.9%)
- ✓Efficient capital deployment (ROCE 21.2%)
- ✓Attractively valued vs sector (P/E 25.7x vs industry 48.9x)
- ✓Low debt relative to equity (D/E 0.1x)
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,783 | ₹4.3L Cr | 34.4 | 5.12 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹6,616 | ₹1.7L Cr | 66.1 | 10.48 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹4,416 | ₹1.5L Cr | 66.4 | 17.81 | 27.6 | 15.4 | 0.33 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,315 | ₹1.2L Cr | 59.5 | 12.62 | 22.1 | 17.9 | 0.88 |
| CIPLA Cipla Limited | ₹1,402 | ₹1.1L Cr | 27.3 | 3.29 | 12.4 | 16.6 | 0.01 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,091 | ₹1.1L Cr | 20 | 4.05 | 21.2 | 21.2 | 0.38 |
| DRREDDY Dr. Reddy's Laboratories Limited | ₹1,283 | ₹1.1L Cr | 25.4 | 2.83 | 11.8 | 13.6 | 0.16 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
ALKEM · as of Mar 2026
Promoters55.13%▼0.53
FII9.40%▼0.74
DII19.42%▲1.41
Public16.05%▼0.14
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 56.74% | 56.74% | 56.38% | 55.66% | 55.66% | 55.13% |
| FII | 8.49% | 9.11% | 8.69% | 9.02% | 10.14% | 9.40% |
| DII | 15.91% | 15.63% | 18.56% | 19.21% | 18.01% | 19.42% |
| Public | 18.86% | 18.51% | 16.37% | 16.12% | 16.19% | 16.05% |
Corporate Events
Meeting of the Board of Directors of the Company is scheduled to be held on Thursday, 28th May, 2026, inter alia:(i) To consider and approve the Standalone and Consolidated Audited Financial Results of the Company for the quarter and financial year ended
Dividend27 May 2026
Interim Dividend - Rs 43 Per Share
Dividend19 Feb 2026
Dividend - Rs 8 Per Share
Dividend7 Aug 2025
Interim Dividend - Rs 37 Per Share
Dividend13 Feb 2025
Dividend - Rs 5 Per Share
Record: 9 Aug 2024
Dividend8 Aug 2024
Interim Dividend - Rs 35 Per Share
Record: 16 Feb 2024
Dividend15 Feb 2024
Dividend - Rs 10 Per Share
Dividend9 Aug 2023
Financials
Quarterly Results
| Metric | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹3.7K Cr ▼6.6% | ₹4.0K Cr ▲18.7% | ₹3.4K Cr ▲7.2% | ₹3.1K Cr ▼6.8% | ₹3.4K Cr ▼1.2% | ₹3.4K Cr ▲12.6% | ₹3.0K Cr ▲3.3% | ₹2.9K Cr |
| Op. Profit | ₹828 Cr ▼10.1% | ₹921 Cr ▲24.6% | ₹739 Cr ▲89.0% | ₹391 Cr ▼48.5% | ₹759 Cr ▲0.8% | ₹753 Cr ▲23.6% | ₹609 Cr ▲51.5% | ₹402 Cr |
| OPM | 22.0% ▼4.3% | 23.0% ▲4.5% | 22.0% ▲83.3% | 12.0% ▼47.8% | 23.0% ▲4.5% | 22.0% ▲10.0% | 20.0% ▲42.9% | 14.0% |
| Net Profit | ₹653 Cr ▼16.2% | ₹779 Cr ▲16.6% | ₹668 Cr ▲107.5% | ₹322 Cr ▼49.8% | ₹641 Cr ▼8.7% | ₹702 Cr ▲27.6% | ₹550 Cr ▲80.9% | ₹304 Cr |
| EPS (₹) | 53.19 ▼16.9% | 63.99 ▲15.2% | 55.56 ▲117.2% | 25.58 ▼51.1% | 52.34 ▼9.1% | 57.6 ▲26.3% | 45.6 ▲85.7% | 24.55 |
Values in ₹ Cr · Source: Screener.in
Annual Profit & Loss
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₹14.7K Cr ▲13.5% | ₹13.0K Cr ▲2.3% | ₹12.7K Cr ▲9.2% | ₹11.6K Cr ▲9.1% | ₹10.6K Cr ▲20.0% | ₹8.9K Cr ▲6.2% | ₹8.3K Cr ▲13.4% | ₹7.4K Cr ▲14.9% | ₹6.4K Cr ▲12.5% | ₹5.7K Cr |
| Expenses | ₹11.7K Cr ▲12.0% | ₹10.5K Cr ▲0.3% | ₹10.4K Cr ▲4.4% | ₹10.0K Cr ▲16.3% | ₹8.6K Cr ▲24.0% | ₹6.9K Cr ▲0.8% | ₹6.9K Cr ▲10.1% | ₹6.2K Cr ▲15.7% | ₹5.4K Cr ▲15.0% | ₹4.7K Cr |
| Op. Profit | ₹3.0K Cr ▲19.6% | ₹2.5K Cr ▲11.7% | ₹2.2K Cr ▲38.7% | ₹1.6K Cr ▼21.0% | ₹2.1K Cr ▲5.6% | ₹1.9K Cr ▲31.8% | ₹1.5K Cr ▲31.8% | ₹1.1K Cr ▲11.0% | ₹1.0K Cr ▲0.8% | ₹1.0K Cr |
| OPM | 20.0% ▲5.3% | 19.0% ▲5.6% | 18.0% ▲28.6% | 14.0% ▼26.3% | 19.0% ▼13.6% | 22.0% ▲22.2% | 18.0% ▲20.0% | 15.0% ▼6.3% | 16.0% ▼11.1% | 18.0% |
| Other Income | ₹409 Cr ▼17.2% | ₹494 Cr ▲165.6% | ₹186 Cr ▲84.2% | ₹101 Cr ▼30.8% | ₹146 Cr ▼36.5% | ₹230 Cr ▲125.5% | ₹102 Cr ▲24.4% | ₹82 Cr ▼28.7% | ₹115 Cr ▲4.5% | ₹110 Cr |
| Interest | ₹161 Cr ▲32.0% | ₹122 Cr ▲8.9% | ₹112 Cr ▲4.7% | ₹107 Cr ▲105.8% | ₹52 Cr ▼11.9% | ₹59 Cr ▼9.2% | ₹65 Cr ▲18.2% | ₹55 Cr ▲0.0% | ₹55 Cr ▲22.2% | ₹45 Cr |
| Depreciation | ₹382 Cr ▲7.0% | ₹357 Cr ▲19.4% | ₹299 Cr ▼3.5% | ₹310 Cr ▲2.0% | ₹304 Cr ▲10.5% | ₹275 Cr ▲8.7% | ₹253 Cr ▲31.1% | ₹193 Cr ▲35.0% | ₹143 Cr ▲41.6% | ₹101 Cr |
| PBT | ₹2.9K Cr ▲13.6% | ₹2.5K Cr ▲24.9% | ₹2.0K Cr ▲55.0% | ₹1.3K Cr ▼29.2% | ₹1.8K Cr ▲0.1% | ₹1.8K Cr ▲46.2% | ₹1.3K Cr ▲31.9% | ₹955 Cr ▲3.1% | ₹926 Cr ▼4.0% | ₹965 Cr |
| Tax % | 18.0% ▲50.0% | 12.0% ▲20.0% | 10.0% ▼56.5% | 23.0% ▲155.6% | 9.0% ▼25.0% | 12.0% ▲33.3% | 9.0% ▼52.6% | 19.0% ▼38.7% | 31.0% ▲416.7% | 6.0% |
| Net Profit | ₹2.4K Cr ▲6.1% | ₹2.2K Cr ▲22.3% | ₹1.8K Cr ▲79.8% | ₹1.0K Cr ▼40.1% | ₹1.7K Cr ▲3.8% | ₹1.6K Cr ▲40.8% | ₹1.1K Cr ▲48.4% | ₹774 Cr ▲21.3% | ₹638 Cr ▼29.5% | ₹905 Cr |
| EPS (₹) | 192.51 ▲6.3% | 181.11 ▲20.6% | 150.19 ▲82.5% | 82.31 ▼40.2% | 137.63 ▲3.8% | 132.57 ▲40.6% | 94.26 ▲48.2% | 63.61 ▲20.5% | 52.77 ▼29.3% | 74.61 |
| Div Payout | 28.0% ▲12.0% | 25.0% ▼7.4% | 27.0% ▼55.7% | 61.0% ▲144.0% | 25.0% ▲8.7% | 23.0% ▼14.8% | 27.0% ▲8.0% | 25.0% ▲0.0% | 25.0% ▲25.0% | 20.0% |
Values in ₹ Cr · Source: Screener.in
Balance Sheet
| Item | Sep 2025 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities | ||||||||||
| Equity Capital | ₹24 Cr ▲0.0% | ₹24 Cr ▲0.0% | ₹24 Cr ▲0.0% | ₹24 Cr ▲0.0% | ₹24 Cr ▲0.0% | ₹24 Cr ▲0.0% | ₹24 Cr ▲0.0% | ₹24 Cr ▲0.0% | ₹24 Cr ▲0.0% | ₹24 Cr |
| Reserves | ₹13.3K Cr ▲11.4% | ₹12.0K Cr ▲16.3% | ₹10.3K Cr ▲14.0% | ₹9.0K Cr ▲4.7% | ₹8.6K Cr ▲17.1% | ₹7.4K Cr ▲19.8% | ₹6.1K Cr ▲13.3% | ₹5.4K Cr ▲11.9% | ₹4.8K Cr ▲8.9% | ₹4.4K Cr |
| Borrowings | ₹2.4K Cr ▲70.6% | ₹1.4K Cr ▼2.6% | ₹1.4K Cr ▲1.5% | ₹1.4K Cr ▼47.6% | ₹2.7K Cr ▲56.3% | ₹1.7K Cr ▲5.6% | ₹1.6K Cr ▲71.2% | ₹944 Cr ▼5.4% | ₹998 Cr ▲51.4% | ₹659 Cr |
| Other Liabilities | ₹4.6K Cr ▲6.0% | ₹4.3K Cr ▲12.5% | ₹3.8K Cr ▲16.0% | ₹3.3K Cr ▲20.0% | ₹2.8K Cr ▲13.5% | ₹2.4K Cr ▲12.3% | ₹2.2K Cr ▲18.9% | ₹1.8K Cr ▲1.2% | ₹1.8K Cr ▲25.2% | ₹1.4K Cr |
| Total Liabilities | ₹20.3K Cr ▲14.7% | ₹17.7K Cr ▲13.6% | ₹15.6K Cr ▲13.2% | ₹13.8K Cr ▼2.2% | ₹14.1K Cr ▲22.1% | ₹11.5K Cr ▲15.8% | ₹9.9K Cr ▲21.2% | ₹8.2K Cr ▲7.1% | ₹7.7K Cr ▲16.7% | ₹6.6K Cr |
| Assets | ||||||||||
| Fixed Assets | ₹3.3K Cr ▲16.4% | ₹2.9K Cr ▼0.7% | ₹2.9K Cr ▲7.1% | ₹2.7K Cr ▼7.5% | ₹2.9K Cr ▲3.9% | ₹2.8K Cr ▼4.0% | ₹2.9K Cr ▲14.9% | ₹2.5K Cr ▲10.8% | ₹2.3K Cr ▲27.1% | ₹1.8K Cr |
| CWIP | ₹653 Cr ▲19.2% | ₹548 Cr ▲244.7% | ₹159 Cr ▼50.8% | ₹323 Cr ▼4.7% | ₹339 Cr ▼13.7% | ₹393 Cr ▲8.3% | ₹363 Cr ▼26.4% | ₹493 Cr ▲29.4% | ₹381 Cr ▲27.4% | ₹299 Cr |
| Investments | ₹2.5K Cr ▲37.2% | ₹1.8K Cr ▲281.4% | ₹484 Cr ▼22.2% | ₹622 Cr ▲67.7% | ₹371 Cr ▲11.4% | ₹333 Cr ▲27.6% | ₹261 Cr ▼19.4% | ₹324 Cr ▼27.0% | ₹444 Cr ▼19.7% | ₹553 Cr |
| Other Assets | ₹13.8K Cr ▲10.8% | ₹12.4K Cr ▲3.2% | ₹12.1K Cr ▲19.1% | ₹10.1K Cr ▼3.1% | ₹10.5K Cr ▲30.7% | ₹8.0K Cr ▲24.7% | ₹6.4K Cr ▲31.9% | ₹4.9K Cr ▲6.7% | ₹4.6K Cr ▲16.3% | ₹3.9K Cr |
| Total Assets | ₹20.3K Cr ▲14.7% | ₹17.7K Cr ▲13.6% | ₹15.6K Cr ▲13.2% | ₹13.8K Cr ▼2.2% | ₹14.1K Cr ▲22.1% | ₹11.5K Cr ▲15.8% | ₹9.9K Cr ▲21.2% | ₹8.2K Cr ▲7.1% | ₹7.7K Cr ▲16.7% | ₹6.6K Cr |
Values in ₹ Cr · Source: Screener.in
Cash Flow Statement
| Item | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating CF | ₹1.9K Cr ▼1.8% | ₹1.9K Cr ▲15.8% | ₹1.7K Cr ▲51.4% | ₹1.1K Cr ▼12.2% | ₹1.3K Cr ▲116.2% | ₹585 Cr ▼25.0% | ₹780 Cr ▲193.2% | ₹266 Cr ▼43.5% | ₹471 Cr ▼35.1% | ₹726 Cr |
| Investing CF | ₹-1.3K Cr ▼27.4% | ₹-1.0K Cr ▼942.5% | ₹120 Cr ▲108.4% | ₹-1.4K Cr ▼44.0% | ₹-995 Cr ▼35.0% | ₹-737 Cr ▼131.8% | ₹-318 Cr ▲9.4% | ₹-351 Cr ▼19.4% | ₹-294 Cr ▼243.4% | ₹205 Cr |
| Financing CF | ₹-811 Cr ▲29.2% | ₹-1.1K Cr ▲35.0% | ₹-1.8K Cr ▼563.4% | ₹380 Cr ▲239.7% | ₹-272 Cr ▼444.3% | ₹79 Cr ▲120.8% | ₹-379 Cr ▼545.9% | ₹85 Cr ▲161.6% | ₹-138 Cr ▲85.1% | ₹-927 Cr |
| Net Cash Flow | ₹-186 Cr ▲10.1% | ₹-207 Cr ▼592.9% | ₹42 Cr ▼27.6% | ₹58 Cr ▲3000.0% | ₹-2 Cr ▲97.3% | ₹-73 Cr ▼189.0% | ₹82 Cr | ₹0 Cr ▼100.0% | ₹40 Cr ▲1233.3% | ₹3 Cr |
| Free Cash Flow | ₹1.3K Cr ▼27.4% | ₹1.8K Cr ▲21.2% | ₹1.5K Cr ▲85.6% | ₹783 Cr ▼29.8% | ₹1.1K Cr ▲370.9% | ₹237 Cr ▼6.3% | ₹253 Cr ▲161.6% | ₹-411 Cr ▼152.1% | ₹-163 Cr ▼134.5% | ₹472 Cr |
Values in ₹ Cr · Source: Screener.in
Key Ratios History
| Metric | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 69d ▲6.2% | 65d ▼3.0% | 67d ▲3.1% | 65d ▼1.5% | 66d ▼8.3% | 72d ▲16.1% | 62d ▲0.0% | 62d ▲34.8% | 46d ▲9.5% | 42d |
| Inventory Days | 224d ▲13.7% | 197d ▲1.5% | 194d ▼26.0% | 262d ▲8.7% | 241d ▲21.7% | 198d ▲6.5% | 186d ▼15.8% | 221d ▲11.6% | 198d ▲17.2% | 169d |
| Days Payable | 141d ▲9.3% | 129d ▲48.3% | 87d ▼14.7% | 102d ▼8.9% | 112d ▲7.7% | 104d ▼12.6% | 119d ▼19.0% | 147d ▲20.5% | 122d ▲13.0% | 108d |
| Cash Conv. Cycle | 152d ▲15.2% | 132d ▼24.1% | 174d ▼22.7% | 225d ▲14.8% | 196d ▲17.4% | 167d ▲29.5% | 129d ▼4.4% | 135d ▲10.7% | 122d ▲18.4% | 103d |
| Working Capital Days | 124d ▼8.1% | 135d ▲104.5% | 66d ▲112.9% | 31d ▼35.4% | 48d ▲9.1% | 44d ▼20.0% | 55d ▲37.5% | 40d ▲17.6% | 34d ▲161.5% | 13d |
| ROCE | 20.0% ▲0.0% | 20.0% ▲42.9% | 14.0% ▼22.2% | 18.0% ▼18.2% | 22.0% ▲22.2% | 18.0% ▲12.5% | 16.0% ▼5.9% | 17.0% ▼19.0% | 21.0% ▼8.7% | 23.0% |
Source: Screener.in · Lower days = better efficiency
Deep Dive Analysis
About Alkem Laboratories Limited
Alkem Laboratories is engaged in pharmaceutical business with global operations. The Company is engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products.(Source : 202003-01 Annual Report Page No:107)
Healthcare · Pharmaceuticals & Biotechnology
Related Analysis
Frequently Asked Questions
What is Alkem Laboratories Limited share price today?▾
Alkem Laboratories Limited (ALKEM) is currently trading at ₹5,250 on NSE, as of the last market session. Prices update daily after market close on MarketNetra.
Is Alkem Laboratories Limited available in F&O (Futures & Options)?▾
Yes, Alkem Laboratories Limited (ALKEM) is part of the NSE F&O segment with a lot size of 125 shares. Options are available with monthly expiry contracts. You can track the full option chain and OI analysis on MarketNetra.
What is Alkem Laboratories Limited 52-week high and low?▾
Alkem Laboratories Limited's 52-week high is ₹5,934 and the 52-week low is ₹4,716. The current price of ₹5,250 is 11.5% below the 52W high.
What is Alkem Laboratories Limited P/E ratio?▾
Alkem Laboratories Limited's current P/E ratio is 25.7. This indicates the market is paying ₹25.7 for every ₹1 of earnings. Compare this to the sector average to assess relative valuation.
How to trade Alkem Laboratories Limited options?▾
Alkem Laboratories Limited options are traded on NSE with monthly expiry contracts (lot size: 125 shares). To trade ALKEM options: select your expiry on the option chain page, identify key OI strikes, check the PCR and buildup type on OI analysis, and review FII/DII flows for institutional sentiment before taking a position.